For the millions living with myasthenia gravis, current treatments are a blunt instrument — broad immunosuppression that suppresses the entire immune system rather than the specific culprits driving muscle weakness. A precision approach published in Nature Communications now demonstrates that engineered T cells can hunt and eliminate only the B cells responsible for producing the damaging autoantibodies, potentially opening a path to durable remission without systemic immune compromise.
The core innovation lies in chimeric autoantibody receptor (CAAR) T cells, a platform that flips the logic of conventional CAR-T cell therapy. Instead of targeting cancer cells, these engineered T cells display extracellular domains of the nicotinic acetylcholine receptor (nAChR) — specifically the α1 and β1 subunits — acting as bait for the autoreactive B cells that produce anti-AChR antibodies. In laboratory assays, AChR CAAR T cells selectively secreted effector cytokines and efficiently lysed B cell targets. In a xenograft mouse model, they depleted pathogenic B cell lines and measurably reduced autoantibody concentrations both in circulation and at the neuromuscular junction itself.
This work builds on a broader CAAR-T research platform previously applied to pemphigus vulgaris, where a similar antigen-display strategy demonstrated proof-of-concept for autoantibody-mediated diseases. The myasthenia gravis application is notable because nAChR autoantibodies are heterogeneous — targeting multiple epitopes — making broad receptor coverage via dual subunit co-transduction a meaningful design choice. Key limitations remain: the evidence is preclinical, relying on xenograft mouse models that incompletely recapitulate human immune dynamics. Longevity and persistence of CAAR-T cells, cytokine release syndrome risk, and off-target B cell depletion in humans are uncharacterized. Nonetheless, for a disease where roughly half of patients fail to achieve sustained remission on existing regimens, this represents a potentially paradigm-shifting therapeutic direction rather than incremental refinement.